Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance-MedSci.cn

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance

Xie, ZH; Gu, YY; Xie, XH; Lin, XQ; Ouyang, M; Qin, YY; Zhang, JX; Lizaso, A; Chen, SY; Zhou, CZ

Zhou, CZ (corresponding author), Guangzhou Med Univ, Dept Resp Med, State Key Lab Resp Dis,Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis,Guangzhou Inst Resp Hl, 151 Yanjiang Rd, Guangzhou 510120, Peoples R China.

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance

科室

工具

服务